LONDON (Reuters) - A genetically engineered herpes virus, designed to kill cancer cells but leave normal tissue unharmed, has shown early promise in clinical tests, scientists said on Saturday.The idea of injecting cancer patients with a live virus may seem bizarre, but researchers believe viruses -- which are experts at killing cells -- could one day become a valuable addition to the medical armory against cancer.
